P1‐037: BASELINE CHARACTERISTICS FOR PATIENTS WITH MILD ALZHEIMER'S DISEASE ENROLLED IN THE PHASE IIA TRIAL OF ACTIVE IMMUNOTHERAPEUTIC VACCINE UB‐311

UB-311 is an active vaccine targeting the Aβ1-14 epitope. An open label Phase I study in patients with mild to moderate Alzheimer's Disease (AD) has been completed, and a placebo-controlled Phase IIa (V203-AD) study is more than half way complete, with last patient out in Q3 2018. The primary endpoints are safety, tolerability and immunogenicity of two different dosing regimens of UB-311 (initial 3 priming doses followed by either 4 booster...